Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "Sleep"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
Kye Won Park, Sungyang Jo, Seung Hyun Lee, Yun Su Hwang, Dagyo Lee, Ho-Sung Ryu, Sun Ju Chung
J Mov Disord. 2020;13(3):205-212.   Published online September 9, 2020
DOI: https://doi.org/10.14802/jmd.20055
  • 7,635 View
  • 273 Download
  • 9 Web of Science
  • 11 Crossref
AbstractAbstract PDF
Objective
To investigate the efficacy of levodopa/carbidopa/entacapone (LCE) at bedtime for treating sleep disturbance in patients with Parkinson’s disease (PD) with motor fluctuations.
Methods
Participants included 128 PD patients with motor fluctuations. All patients were assessed for motor, nonmotor, and sleep-specific symptoms using the United Parkinson’s Disease Rating Scale (UPDRS), the Korean version of the Nonmotor Symptom Scale, the Parkinson’s Disease Sleep Scale (PDSS), the Epworth Sleepiness Scale, and the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ). We compared the baseline characteristics of patients with sleep disturbance (PDSS score < 120) and those without sleep disturbance (PDSS score ≥ 120). Thirty-nine patients with sleep disturbance who agreed to take LCE at bedtime completed 3-month follow-ups. We analyzed changes in the scores of motor, nonmotor, and sleep symptom scales over the 3 months.
Results
PD patients with sleep disturbance were at more advanced disease stages and had more severe motor, nonmotor, and sleep symptoms than those without sleep disturbance. Patients who took LCE at night showed improvements in motor (UPDRS part III, p = 0.007) and sleep symptoms (total PDSS, p < 0.001). Sleep features that benefitted from LCE included not only nocturnal motor components but also insomnia (PDSS items 2 and 3, p = 0.005 and p < 0.001) and rapid eye movement behavior disorder (PDSS item 6, p = 0.002; and RBDSQ, p < 0.001).
Conclusion
The use of LCE at bedtime may be a useful treatment for sleep disturbance in advanced PD patients with motor fluctuations.

Citations

Citations to this article as recorded by  
  • Comparison of sleep characteristics between Parkinson's disease with and without freezing of gait: A systematic review
    Tracy Milane, Clint Hansen, Mathias Baptiste Correno, Matthias Chardon, Fabio A. Barbieri, Edoardo Bianchini, Nicolas Vuillerme
    Sleep Medicine.2024; 114: 24.     CrossRef
  • Opicapone versus entacapone: Head‐to‐head retrospective data‐based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol‐O‐methyltransferase (COMT) inhibitor treatment
    Glynn Harrison‐Jones, Xiaocong Li Marston, Francesca Morgante, K. Ray Chaudhuri, Guillermo Castilla‐Fernández, Valentina Di Foggia
    European Journal of Neurology.2023; 30(10): 3132.     CrossRef
  • Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
    Michael Howell, Alon Y. Avidan, Nancy Foldvary-Schaefer, Roneil G. Malkani, Emmanuel H. During, Joshua P. Roland, Stuart J. McCarter, Rochelle S. Zak, Gerard Carandang, Uzma Kazmi, Kannan Ramar
    Journal of Clinical Sleep Medicine.2023; 19(4): 769.     CrossRef
  • The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
    Valentina Leta, Daniel J. van Wamelen, Federico Aureli, Vinod Metta, Dhaval Trivedi, Pietro Cortelli, Carmen Rodriguez-Blazquez, Alexandra Rizos, K. Ray Chaudhuri
    Journal of Neural Transmission.2023; 130(7): 925.     CrossRef
  • Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
    P. Tall, M. A. Qamar, L. Batzu, V. Leta, C. Falup-Pecurariu, K. Ray Chaudhuri
    Journal of Neural Transmission.2023; 130(11): 1443.     CrossRef
  • Tenuigenin promotes non-rapid eye movement sleep via the GABAA receptor and exerts somnogenic effect in a MPTP mouse model of Parkinson's disease
    Di Zhang, Wenjing Zhang, Shumin Deng, Lu Liu, Hua Wei, Fenqin Xue, Hui Yang, Xiaomin Wang, Zheng Fan
    Biomedicine & Pharmacotherapy.2023; 165: 115259.     CrossRef
  • Neurological Insights into Sleep Disorders in Parkinson’s Disease
    Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn, Chaiyavat Chaiyasut
    Brain Sciences.2023; 13(8): 1202.     CrossRef
  • Real‐world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo®) in Parkinson's disease
    Heinz Reichmann
    European Journal of Neurology.2023; 30(S2): 15.     CrossRef
  • Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson’s disease
    Karina A. Atanasova-Ivanova, Sonya Ivanova Hristova-Chakmakova, Ivan G. Milanov
    Folia Medica.2023; 65(6): 929.     CrossRef
  • The Home-Based Sleep Laboratory
    Yael Hanein, Anat Mirelman, Anat Mirelman, E. Ray Dorsey, Patrik Brundin, Bastiaan R. Bloem
    Journal of Parkinson's Disease.2021; 11(s1): S71.     CrossRef
  • Shudi Pingchan Decoction combined with repetitive transcranial magnetic stimulation in the treatment of Parkinson’s disease with sleep disorders
    Qing Ye, Xiqun Chen, Yuqing Hu, Jie Zhou, Chen Gao, Zhenguo Liu
    Traditional Medicine and Modern Medicine.2020; 03(02): 85.     CrossRef
The Non-Motor Symptom Profile of Progressive Supranuclear Palsy
Sudhakar Pushpa Chaithra, Shweta Prasad, Vikram Venkappayya Holla, Albert Stezin, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal
J Mov Disord. 2020;13(2):118-126.   Published online April 6, 2020
DOI: https://doi.org/10.14802/jmd.19066
  • 7,761 View
  • 256 Download
  • 17 Web of Science
  • 13 Crossref
AbstractAbstract PDF
Objective
Non-motor symptoms (NMSs) significantly contribute to increased morbidity and poor quality of life in patients with parkinsonian disorders. This study aims to explore the profile of NMSs in patients with progressive supranuclear palsy (PSP) using the validated Non-Motor Symptom Scale (NMSS).
Methods
Seventy-six patients with PSP were evaluated in this study. Motor symptoms and NMSs were evaluated using the PSP Rating Scale (PSPRS), Unified Parkinson’s Disease Rating Scale-III, Montreal Cognitive Assessment, Hamilton Depression (HAMD) and Anxiety Rating Scales, Parkinson’s Disease Sleep Scale (PDSS) and NMSS. NMS severity and prevalence were also compared between patients with PSP-Richardson syndrome (PSP-RS) and those with PSP-parkinsonism.
Results
All subjects in this cohort reported at least 2 NMSs. The most prevalent NMSs in patients with PSP were in the domains of sleep/fatigue, mood/cognition, and sexual function. The least prevalent NMSs were in the domains of cardiovascular including falls, and perceptual problems/hallucinations. Significant correlations were observed between the NMSS scores and HAM-D, PDSS, PSPRS scores and PSPRS sub-scores. The severity of NMSs was unrelated to the duration of illness. Patients with PSP-RS reported a higher severity of drooling, altered smell/taste, depression and altered interest in sex and a higher prevalence of sexual dysfunction.
Conclusion
NMSs are commonly observed in patients with PSP, and the domains of sleep, mood and sexual function are most commonly affected. These symptoms contribute significantly to disease morbidity, and clinicians should pay adequate attention to identifying and addressing these symptoms.

Citations

Citations to this article as recorded by  
  • Autonomic dysfunction in progressive supranuclear palsy
    Francesca Baschieri, Maria Vitiello, Pietro Cortelli, Giovanna Calandra-Buonaura, Francesca Morgante
    Journal of Neurology.2023; 270(1): 109.     CrossRef
  • PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy
    Xin-Yi Li, Ming-Jia Chen, Xiao-Niu Liang, Rui-Xin Yao, Bo Shen, Bin Wu, Gen Li, Yi-Min Sun, Jian-Jun Wu, Feng-Tao Liu, Yu-Jie Yang, Jian Wang
    Journal of Parkinson's Disease.2023; 13(1): 83.     CrossRef
  • Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy
    Wen-Zheng Hu, Ling-Xiao Cao, Jin-Hui Yin, Xue-Song Zhao, Ying-Shan Piao, Wei-Hong Gu, Jing-Hong Ma, Zhi-Rong Wan, Yue Huang
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Neurological update: the palliative care landscape for atypical parkinsonian syndromes
    Noreen O’Shea, Shane Lyons, Stephen Higgins, Sean O’Dowd
    Journal of Neurology.2023; 270(4): 2333.     CrossRef
  • Structural correlates of survival in progressive supranuclear palsy
    Duncan Street, W Richard Bevan-Jones, Maura Malpetti, P Simon Jones, Luca Passamonti, Boyd CP. Ghosh, Timothy Rittman, Ian TS. Coyle-Gilchrist, Kieren Allinson, Catherine E. Dawson, James B. Rowe
    Parkinsonism & Related Disorders.2023; 116: 105866.     CrossRef
  • Migraine and Tension-type Headache in Parkinson’s Disease and Progressive Supranuclear Palsy/Corticobasal Syndrome
    Vinayak Jatale, Ashutosh Tiwari, Mritunjai Kumar, Ravi Gupta, Niraj Kumar
    Annals of Indian Academy of Neurology.2023; 26(5): 708.     CrossRef
  • A Systematic Review of Apathy and Depression in Progressive Supranuclear Palsy
    Joshua Flavell, Peter J. Nestor
    Journal of Geriatric Psychiatry and Neurology.2022; 35(3): 280.     CrossRef
  • The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study
    Demetris Pillas, Alexander Klein, Teresa Gasalla, Andreja Avbersek, Alexander Thompson, Jack Wright, Jennifer Mellor, Anna Scowcroft
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Fatigue in hypokinetic, hyperkinetic, and functional movement disorders
    Ilaria Antonella Di Vico, Giovanni Cirillo, Alessandro Tessitore, Mattia Siciliano, Massimo Venturelli, Cristian Falup-Pecurariu, Gioacchino Tedeschi, Francesca Morgante, Michele Tinazzi
    Parkinsonism & Related Disorders.2021; 86: 114.     CrossRef
  • Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study
    Rachel Rohmann, Eva Kühn, Raphael Scherbaum, Lovis Hilker, Saskia Kools, Leonard Scholz, Katharina Müller, Sophie Huckemann, Christiane Schneider-Gold, Ralf Gold, Kalliopi Pitarokoili, Lars Tönges, Eun Hae Kwon
    Brain Sciences.2021; 11(7): 879.     CrossRef
  • Understanding fatigue in progressive supranuclear palsy
    Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho
    Scientific Reports.2021;[Epub]     CrossRef
  • “Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism
    Ján Necpál, Miroslav Borsek, Bibiána Jeleňová
    Neurological Sciences.2021; 42(12): 4927.     CrossRef
  • Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
    Duncan Street, Maura Malpetti, Timothy Rittman, Boyd C P Ghosh, Alexander G Murley, Ian Coyle-Gilchrist, Luca Passamonti, James B Rowe
    Brain Communications.2021;[Epub]     CrossRef
Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment
Jee-Young Lee, Eun Jin Yoon, Yu Kyeong Kim, Chae Won Shin, Hyunwoo Nam, Jae Min Jeong, Han-Joon Kim, Beomseok Jeon
J Mov Disord. 2019;12(2):103-112.   Published online May 30, 2019
DOI: https://doi.org/10.14802/jmd.18061
  • 7,069 View
  • 205 Download
  • 18 Web of Science
  • 17 Crossref
AbstractAbstract PDFSupplementary Material
Objective
It is unclear whether the decline in dopamine transporters (DAT) differs among idiopathic rapid eye movement sleep behavior disorder (iRBD) patients with different levels of olfactory impairment. This study aimed to characterize DAT changes in relation to nonmotor features in iRBD patients by olfactory loss.
Methods
This prospective cohort study consisted of three age-matched groups: 30 polysomnography-confirmed iRBD patients, 30 drug-naïve Parkinson’s disease patients, and 19 healthy controls without olfactory impairment. The iRBD group was divided into two groups based on olfactory testing results. Participants were evaluated for reported prodromal markers and then underwent 18F-FP-CIT positron emission tomography and 3T MRI. Tracer uptakes were analyzed in the caudate, anterior and posterior putamen, substantia nigra, and raphe nuclei.
Results
Olfactory impairment was defined in 38.5% of iRBD patients. Mild parkinsonian signs and cognitive functions were not different between the two iRBD subgroups; however, additional prodromal features, constipation, and urinary and sexual dysfunctions were found in iRBD patients with olfactory impairment but not in those without. Tracer uptake showed significant group differences in all brain regions, except the raphe nuclei. The iRBD patients with olfactory impairment had uptake reductions in the anterior and posterior putamen, caudate, and substantia nigra (p < 0.016 in all, adjusted for age), which ranged from 0.6 to 0.8 of age-normative values. In contrast, those without olfactory impairment had insignificant changes in all regions ranging above 0.8.
Conclusion
There was a clear distinction in DAT loss and nonmotor profiles by olfactory status in iRBD.

Citations

Citations to this article as recorded by  
  • Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies
    Caterina Leitner, Giada D’Este, Laura Verga, Shady Rahayel, Samantha Mombelli, Marco Sforza, Francesca Casoni, Marco Zucconi, Luigi Ferini-Strambi, Andrea Galbiati
    Neuropsychology Review.2024; 34(1): 41.     CrossRef
  • Dopamine transporter positron emission tomography in patients with Alzheimer’s disease with Lewy body disease features
    Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye
    Neurobiology of Aging.2024; 134: 57.     CrossRef
  • Imaging Procedure and Clinical Studies of [18F]FP-CIT PET
    Changhwan Sung, Seung Jun Oh, Jae Seung Kim
    Nuclear Medicine and Molecular Imaging.2024;[Epub]     CrossRef
  • Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
    Beatrice Orso, Pietro Mattioli, Eun-Jin Yoon, Yu Kyeong Kim, Heejung Kim, Jung Hwan Shin, Ryul Kim, Claudio Liguori, Francesco Famà, Andrea Donniaquio, Federico Massa, David Vállez García, Sanne K. Meles, Klaus L. Leenders, Agostino Chiaravalloti, Matteo
    Neurological Sciences.2023; 44(9): 3161.     CrossRef
  • Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder
    Don Gueu Park, Ju Yeong Kim, Min Seung Kim, Mi Hee Kim, Young-Sil An, Jaerak Chang, Jung Han Yoon
    Journal of Neurology.2023; 270(9): 4393.     CrossRef
  • Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study
    Jung Hwan Shin, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyunwoo Nam, Beomseok Jeon, Jee-Young Lee
    Translational Neurodegeneration.2023;[Epub]     CrossRef
  • Brain olfactory‐related atrophy in isolated rapid eye movement sleep behavior disorder
    Kyung Ah Woo, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Hyunwoo Nam, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee
    Annals of Clinical and Translational Neurology.2023; 10(12): 2192.     CrossRef
  • Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease
    Kyung Ah Woo, Joo Hong Joun, Eun Jin Yoon, Chan Young Lee, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee
    Movement Disorders.2023; 38(12): 2291.     CrossRef
  • Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features
    Zhaoxi Liu, Yiwei Zhang, Han Wang, Dan Xu, Hui You, Zhentao Zuo, Feng Feng
    Neurological Research.2022; 44(1): 47.     CrossRef
  • Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Systematic Review
    Rafail Matzaras, Kuangyu Shi, Artemios Artemiadis, Panagiotis Zis, Georgios Hadjigeorgiou, Axel Rominger, Claudio L.A. Bassetti, Panagiotis Bargiotas
    Journal of Parkinson's Disease.2022; 12(1): 69.     CrossRef
  • Odor Identification by Parkinson’s Disease Patients Tested by Using Sniffin’ Sticks versus Natural Spices
    Florence Baert, Geertrui Vlaemynck, Jarissa Maselyne, Christophe Matthys, Seyed-Mohammad Fereshtehnejad
    Parkinson's Disease.2022; 2022: 1.     CrossRef
  • Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease
    Ryul Kim, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyun Woo Nam, Beomseok Jeon, Jee‐Young Lee
    Movement Disorders.2022; 37(10): 2099.     CrossRef
  • Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder‐Related Metabolic Pattern Expression
    Ryul Kim, Jee‐Young Lee, Yu Kyeong Kim, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Dallah Yoo, Hyunwoo Nam, Beomseok Jeon
    Movement Disorders.2021; 36(8): 1889.     CrossRef
  • Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder
    Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Eun Jin Yoon, Heejung Kim, Hyunwoo Nam, Beomseok Jeon
    Neurology.2021;[Epub]     CrossRef
  • Retina Thickness as a Marker of Neurodegeneration in Prodromal Lewy Body Disease
    Jee‐Young Lee, Jeeyun Ahn, Sohee Oh, Joo Young Shin, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon
    Movement Disorders.2020; 35(2): 349.     CrossRef
  • Serum TNF-α and neurodegeneration in isolated REM sleep behavior disorder
    Ryul Kim, Jee-Young Lee, Han-Joon Kim, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon
    Parkinsonism & Related Disorders.2020; 81: 1.     CrossRef
  • Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
    Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Sung-A Shin, Heejung Kim, Hyunwoo Nam, Beomseok Jeon
    Neurology.2020;[Epub]     CrossRef
Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
Suk Yun Kang, Ho-Sung Ryu, Mun-Kyung Sunwoo, Sang-Jin Kim, Jong-Sam Baik, Mee-Young Park, Hyung-Eun Park, Joong-Seok Kim, Kyum-Yil Kwon, Seong-Beom Koh, Young-Eun Kim, Mi-Kyong Lee, Jong-Min Kim, Sun Ju Chung, Young-Ho Sohn
J Mov Disord. 2017;10(3):123-129.   Published online September 22, 2017
DOI: https://doi.org/10.14802/jmd.17048
  • 9,017 View
  • 191 Download
  • 12 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Objective
We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s disease (PD) with a large population.
Methods
We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
Results
Four-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.
Conclusion
Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.

Citations

Citations to this article as recorded by  
  • Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: a multicenter cross-sectional study
    Remi Morimoto, Mutsumi Iijima, Yasuyuki Okuma, Keisuke Suzuki, Fumihito Yoshii, Shigeru Nogawa, Takashi Osada, Kazuo Kitagawa
    Frontiers in Aging Neuroscience.2023;[Epub]     CrossRef
  • Excessive Daytime Sleepiness in Parkinson’s Disease
    Hanshu Liu, Jingwen Li, Xinyi Wang, Jinsha Huang, Tao Wang, Zhicheng Lin, Nian Xiong
    Nature and Science of Sleep.2022; Volume 14: 1589.     CrossRef
  • Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis
    Fei Feng, YingYing Cai, YanBing Hou, Ruwei Ou, Zheng Jiang, HuiFang Shang
    Parkinsonism & Related Disorders.2021; 85: 133.     CrossRef
  • Sleep Disorders and Cognitive Dysfunctions in Parkinson’s Disease: A Meta-Analytic Study
    Gianpaolo Maggi, Luigi Trojano, Paolo Barone, Gabriella Santangelo
    Neuropsychology Review.2021; 31(4): 643.     CrossRef
  • Longitudinal risk factors for developing depressive symptoms in Parkinson's disease
    Tarek Antar, Huw R. Morris, Faraz Faghri, Hampton L. Leonard, Mike A. Nalls, Andrew B. Singleton, Hirotaka Iwaki
    Journal of the Neurological Sciences.2021; 429: 117615.     CrossRef
  • The effect and safety of ropinirole in the treatment of Parkinson disease
    Jiali Zhu, Min Chen
    Medicine.2021; 100(46): e27653.     CrossRef
  • Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease
    Shi-Zhuang Wei, Xiao-Yu Yao, Chen-Tao Wang, An-Qi Dong, Dan Li, Yu-Ting Zhang, Chao Ren, Jin-Bao Zhang, Cheng-Jie Mao, Fen Wang, Chun-Feng Liu
    Brain Research Bulletin.2021; 177: 363.     CrossRef
  • A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats
    Mahino Fatima, Mir Hilal Ahmad, Saurabh Srivastav, Moshahid Alam Rizvi, A.C. Mondal
    Neurochemistry International.2020; 136: 104730.     CrossRef
  • ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine
    Silvia Rota, Iro Boura, Lucia Batzu, Nataliya Titova, Peter Jenner, Cristian Falup-Pecurariu, K Ray Chaudhuri
    Expert Review of Neurotherapeutics.2020; 20(9): 953.     CrossRef
  • An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression
    Teng-Hong Lian, Peng Guo, Li-Jun Zuo, Yang Hu, Shu-Yang Yu, Li Liu, Zhao Jin, Qiu-Jin Yu, Rui-Dan Wang, Li-Xia Li, Ying-Shan Piao, Wei Zhang
    Frontiers in Psychiatry.2019;[Epub]     CrossRef
Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Preliminary Study
Chang Soo Kim, Young Hee Sung, Min Ju Kang, Kee Hyung Park
J Mov Disord. 2016;9(2):114-119.   Published online March 2, 2016
DOI: https://doi.org/10.14802/jmd.15039
  • 16,106 View
  • 149 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Objective
Rapid eye movement sleep behavior disorder (RBD) is associated with α-synucleinopathies, such as Parkinson’s disease (PD). We aimed to assess the differences in the clinical characteristics of PD with and without RBD.
Methods
Forty-two patients previously diagnosed with PD were evaluated for clinical history, motor and cognitive functioning using the Unified Parkinson’s Disease Rating Scale (UPDRS) and Mini-Mental State Examination (MMSE), autonomic symptoms, sleep characteristics using the Pittsburg Sleep Quality Index (PSQI), and the presence of RBD using the Korean version of the RBD screening questionnaire (RBDSQ). The prevalence of RBD and the patients’ demographic features were evaluated. The patients were classified into two groups, PD with RBD and PD without RBD, based on the RBDSQ scores. The motor and cognitive functions, as well as other clinical features of the two groups were compared.
Results
A total of 42 PD patients were enrolled. Eighteen patients were classified as PD with RBD. Compared to PD without RBD, PD with RBD showed higher scores of rigidity in the UPDRS subscale. Regarding sleep problems, PD with RBD revealed higher sleep disturbance, lower sleep efficiency, and lower overall sleep quality in the PSQI. There was no difference in cognitive dysfunction between the two groups according to the Korean version of the MMSE.
Conclusions
PD with RBD was associated with poorer sleep and motor symptoms. Therefore, RBD symptoms in PD are possibly poor prognostic markers.

Citations

Citations to this article as recorded by  
  • Cerebellar Microstructural Abnormalities in Parkinson’s Disease: a Systematic Review of Diffusion Tensor Imaging Studies
    Maryam Haghshomar, Parnian Shobeiri, Seyed Arsalan Seyedi, Fatemeh Abbasi-Feijani, Amirhossein Poopak, Houman Sotoudeh, Arash Kamali, Mohammad Hadi Aarabi
    The Cerebellum.2022; 21(4): 545.     CrossRef
  • A data-driven system to identify REM sleep behavior disorder and to predict its progression from the prodromal stage in Parkinson's disease
    Matteo Cesari, Julie A.E. Christensen, Maria-Lucia Muntean, Brit Mollenhauer, Friederike Sixel-Döring, Helge B.D. Sorensen, Claudia Trenkwalder, Poul Jennum
    Sleep Medicine.2021; 77: 238.     CrossRef
  • Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease
    Mohamed Elfil, Eshak I. Bahbah, Mahmoud M. Attia, Mohamed Eldokmak, Brian B. Koo
    Movement Disorders.2021; 36(3): 570.     CrossRef
  • Sleep Disorders and Cognitive Dysfunctions in Parkinson’s Disease: A Meta-Analytic Study
    Gianpaolo Maggi, Luigi Trojano, Paolo Barone, Gabriella Santangelo
    Neuropsychology Review.2021; 31(4): 643.     CrossRef
  • Risk stratification for REM sleep behavior disorder in patients with Parkinson’s disease: A PRISMA-compliant meta-analysis and systematic review
    Chengjuan Xie, Mingyu Zhu, Ying Hu
    Clinical Neurology and Neurosurgery.2021; 202: 106484.     CrossRef
  • REM sleep behavior disorder portends poor prognosis in Parkinson’s disease: A systematic review
    Yoon Kim, Young Eun Kim, Eun Ok Park, Chae Won Shin, Han-Joon Kim, Beomseok Jeon
    Journal of Clinical Neuroscience.2018; 47: 6.     CrossRef
  • Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis
    Xiaona Zhang, Xiaoxuan Sun, Junhong Wang, Liou Tang, Anmu Xie
    Neurological Sciences.2017; 38(1): 163.     CrossRef
  • Clinical variations in Parkinson’s disease patients with or without REM sleep behaviour disorder: a meta-analysis
    Ruo-lin Zhu, Cheng-juan Xie, Pan-pan Hu, Kai Wang
    Scientific Reports.2017;[Epub]     CrossRef
Correlation of Sleep Disturbance and Cognitive Impairment in Patients with Parkinson’s Disease
Eun Ja Kim, Joon Hyun Baek, Dong Jin Shin, Hyeon-Mi Park, Yeong-Bae Lee, Kee-Hyung Park, Dong Hoon Shin, Young Noh, Young Hee Sung
J Mov Disord. 2014;7(1):13-18.   Published online April 30, 2014
DOI: https://doi.org/10.14802/jmd.14003
  • 13,480 View
  • 112 Download
  • 10 Web of Science
  • 11 Crossref
AbstractAbstract PDF
Objective: Cognitive impairment is a common nonmotor symptom of Parkinson’s disease (PD) and is associated with high mortality, caregiver distress, and nursing home placement. The risk factors for cognitive decline in PD patients include advanced age, longer disease duration, rapid eye movement sleep behavior disorder, hallucinations, excessive daytime sleepiness, and nontremor symptoms including bradykinesia, rigidity, postural instability, and gait disturbance. We conducted a cross-sectional study to determine which types of sleep disturbances are related to cognitive function in PD patients.
Methods: A total of 71 PD patients (29 males, mean age 66.46 ± 8.87 years) were recruited. All patients underwent the Mini- Mental State Examination (MMSE) and the Korean Version of the Montreal Cognitive Assessments (MoCA-K) to assess global cognitive function. Sleep disorders were evaluated with the Stanford Sleepiness Scale, Epworth Sleepiness Scale, Insomnia Severity Index (ISI), Pittsburg Sleep Quality Index, and Parkinson’s Disease Sleep Scale in Korea (PDSS).
Results: The ISI was correlated with the MMSE, and total PDSS scores were correlated with the MMSE and the MoCA-K. In each item of the PDSS, nocturnal restlessness, vivid dreams, hallucinations, and nocturnal motor symptoms were positively correlated with the MMSE, and nocturnal restlessness and vivid dreams were significantly related to the MoCA-K. Vivid dreams and nocturnal restlessness are considered the most powerful correlation factors with global cognitive function, because they commonly had significant correlation to cognition assessed with both the MMSE and the MoCA-K.

Conclusions: We found a correlation between global cognitive function and sleep disturbances, including vivid dreams and nocturnal restlessness, in PD patients.

Citations

Citations to this article as recorded by  
  • Assessing the Safety and Therapeutic Efficacy of Cannabidiol Lipid Nanoparticles in Alleviating Metabolic and Memory Impairments and Hippocampal Histopathological Changes in Diabetic Parkinson’s Rats
    Sarawut Lapmanee, Sakkarin Bhubhanil, Prapimpun Wongchitrat, Natthawut Charoenphon, Anjaree Inchan, Thitaphat Ngernsutivorakul, Piroonrat Dechbumroong, Mattaka Khongkow, Katawut Namdee
    Pharmaceutics.2024; 16(4): 514.     CrossRef
  • Evaluation and validation of a patient-reported quality-of-life questionnaire for Parkinson’s disease
    Pantelis Stathis, George Papadopoulos
    Journal of Patient-Reported Outcomes.2022;[Epub]     CrossRef
  • Poor sleep quality is associated with fatigue and depression in early Parkinson's disease: A longitudinal study in the PALS cohort
    Matthew Rui En Koh, Cong Yang Chua, Samuel Yong-Ern Ng, Nicole Shuang-Yu Chia, Seyed Ehsan Saffari, Regina Yu-Ying Chen, Xinyi Choi, Dede Liana Heng, Shermyn Xiumin Neo, Kay Yaw Tay, Wing Lok Au, Eng-King Tan, Louis Chew-Seng Tan, Zheyu Xu
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Dream Content Predicts Motor and Cognitive Decline in Parkinson's Disease
    Abidemi I. Otaiku
    Movement Disorders Clinical Practice.2021; 8(7): 1041.     CrossRef
  • The impact of clinical scales in Parkinson’s disease: a systematic review
    Nikita Aggarwal, Barjinder Singh Saini, Savita Gupta
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.2021;[Epub]     CrossRef
  • Depressive symptoms effect subjective sleep quality in Chinese patients with Parkinson’s disease
    Jun Zhu, Min Zhong, Jun Yan, Zhuang Wu, Yang Pan, Bo Shen, Jingde Dong, Li Zhang
    Clinical Neurology and Neurosurgery.2020; 195: 105950.     CrossRef
  • Effects of agomelatine in rotenone-induced Parkinson’s disease in rats
    Caner Günaydın, Bahattin Avcı, Ayhan Bozkurt, Mehmet Emin Önger, Hakan Balcı, S. Sırrı Bilge
    Neuroscience Letters.2019; 699: 71.     CrossRef
  • Sleep quality is associated with the severity of clinical symptoms in Parkinson’s disease
    Bruno T. Junho, Arthur Kummer, Francisco E. Cardoso, Antonio L. Teixeira, Natalia P. Rocha
    Acta Neurologica Belgica.2018; 118(1): 85.     CrossRef
  • Circadian Rest‐Activity Rhythms Predict Cognitive Function in Early Parkinson's Disease Independently of Sleep
    Jade Q. Wu, Peng Li, Karina Stavitsky Gilbert, Kun Hu, Alice Cronin‐Golomb
    Movement Disorders Clinical Practice.2018; 5(6): 614.     CrossRef
  • Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson’s Disease
    Seok Jong Chung, Yong-Ho Choi, Hunki Kwon, Yeong-Hun Park, Hyuk Jin Yun, Han Soo Yoo, Seock Hyeon Moon, Byoung Seok Ye, Young H. Sohn, Jong-Min Lee, Phil Hyu Lee
    Sleep.2017;[Epub]     CrossRef
  • Schlaf und Schlafstörungen bei alten Menschen
    Jeanina Schlitzer, Helmut Frohnhofen
    DNP - Der Neurologe und Psychiater.2015; 16(4): 53.     CrossRef

JMD : Journal of Movement Disorders